Clinical trials: Human Papillomavirus Vaccines
Infections, Papillomavirus
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current phase 3b study is designed to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV…
- Trial name
- NCT00552279
- Testing
- Cervarix TM
- Where
- 16 sites in Italy, Romania and 1 more
- Volunteers
- 805 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Vaccines
Increasing HPV Vaccination in Community-Based Pediatric Practices
The central goal of this study is to identify the optimal approach to implementing an evidence-based practice facilitation (PF) intervention for the uptake and completion of HPV vaccine among adolescents receiving care in the…
- Trial name
- NCT03399396
- Testing
- Practice facilitation for HPV vaccine
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Pamela Hull
Human Papilloma Virus, Warts
Intralesional HPV Vaccine for Condylomata
This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
- Conditions
- Human Papilloma Virus, Warts, Warts, Genital, Condyloma
- Trial name
- NCT05087849
- Testing
- nonavalent human papillomavirus vaccine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
HPV Vaccines
Giving Immunizations Through Vaccine Education
This study will test the effectiveness of clinician-focused health IT-based decision support, family-focused health IT-based decision support, and a combination of both efforts, in increasing HPV and other adolescent vaccine…
- Trial name
- GIVE (NCT01159093)
- Testing
- Family Decision Support, Clinician Decision Support, Family Decision Support and Clinician Decision Support
- Where
- United States
- Volunteers
- 23,675 people
- Sponsor
- Children's Hospital of Philadelphia
Papillomavirus Vaccines
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
The focus of this research is on increasing the uptake of the human papillomavirus (HPV) vaccine in young cancer survivors, a vulnerable population at high risk for developing new cancers (such as cervical and anal cancer) caused…
- Trial name
- NCT04469569
- Testing
- HPV-PROTECT
- Where
- 6 sites in United States
- Volunteers
- 8,120 people
- Sponsor
- University of Alabama at Birmingham
HPV Vaccination Rates, HPV Vaccine Awareness
Effectiveness of Large Language Model-Based Chatbot Among Parents of Junior High School Girls in Improving Human Papillomavirus (HPV) Vaccine Awareness, Intention and Vaccination Rates
This is an interventional study targeting parents of junior high school girls. The primary objective of the study is to evaluate the effectiveness of a vaccine chatbot in improving HPV vaccination rates among parents' junior high…
- Conditions
- HPV Vaccination Rates, HPV Vaccine Awareness, HPV Vaccination Intention
- Trial name
- NCT07525245
- Testing
- Scientific videos, Vaccine chatbot
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Behavior, Information Seeking, Intention
Testing Messages to Promote HPV Vaccination
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. Hispanic women have the highest rates of HPV-related cervical cancer compared to all other groups in the U.S.
- Conditions
- Behavior, Information Seeking, Intention, Vaccine Hesitancy
- Trial name
- NCT05206669
- Testing
- Health Messages
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cervical Cancer
Acceptability and Feasibility of Human Papilloma Virus Vaccine
The overall program goal is to determine the Acceptability and Feasibility of introducing a population based Human Papilloma Virus (HPV) Vaccination programme and understanding the key individual and community factors that would…
- Trial name
- NCT01209338
- Testing
- Health education
- Where
- India
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Hospital
Patient Compliance, Health Knowledge, Attitudes, Practice
Electronic Messaging to Increase Human Papillomavirus Vaccine Utilization and Adherence Among College Students
Introduction: Although vaccination against HPV and subsequent HPV-related cancers is a significant breakthrough, uptake is low. We sought to understand whether a low-cost intervention of electronic (text and/or email) appointment…
- Trial name
- NCT01568515
- Testing
- Electronic Message
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- East Carolina University
Infections, Papillomavirus
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
This study has been designed to evaluate the immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine when administered according to alternative 2-dose schedules (0,6 months and 0,12 months) in healthy 9-14 year old…
- Trial name
- NCT01381575
- Testing
- GSK Biologicals' HPV vaccine 580299
- Where
- 33 sites in Canada, Germany and 3 more
- Volunteers
- 1,447 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV, Human Papillomavirus
Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults
The purpose of this study is to analyze and compare the immunogenicity of Bivalent and Tetravalent vaccines against Human Papillomavirus in HIV-infected adult persons.
- Trial name
- HIPAVAC (NCT01386164)
- Testing
- Gardasil, Cervarix
- Where
- Denmark
- Volunteers
- 92 people
- Sponsor
- University of Aarhus
HPV, Cervical Cancer
Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
This dose-ranging study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate that the vaccine is well-tolerated in women (2) To evaluate immune responses in women who are between 16 and 23…
- Conditions
- HPV, Cervical Cancer, Premalignancy Anogenital Warts
- Trial name
- NCT00260039
- Testing
- Comparator: Gardasil, Comparator: octavalent HPV Vaccine - dose formulation 1, Comparator: octavalent HPV Vaccine - dose formulation 2
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Vulvar Cancer
Education, Immigration and HPV Vaccination: an Informational Randomized Trial
Counteracting misinformation on childhood vaccines remains a priority for public health in industrialized countries. Previous research showed that misinformation-induced vaccine hesitancy particularly concerns very highly or very…
- Conditions
- Cervical Cancer, Vulvar Cancer, Anus Cancer, Penis Cancer
- Trial name
- NCT04905030
- Testing
- Information T1, Information T2, Information C
- Where
- Sweden
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Cancer of Cervix, Vaccinia
The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years
A nonrandomized, non-double blinded prospective cohort study to evaluate the preventive efficacy of quadrivalent HPV6/11/16/18 vaccine for the persistent infection of HPV16 genotype or HPV18 genotype in Japanese women aged 27-45…
- Trial name
- NCT04022148
- Testing
- Gardasil
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- University of Fukui
Healthy Subject
HPV Vaccine Intervention for Young Sexual Minority Men
This phase III trial studies how well the Outsmart HPV intervention works in increasing HPV vaccine initiation and completion among young individuals who report having a history of same-sex partners, being sexually attracted to…
- Trial name
- NCT04032106
- Testing
- Best Practice, Informational Intervention, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 1,227 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Human Papillomavirus
Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.
Two human papillomavirus vaccines are now commercially available. No clinical data exist regarding: The immunogenicity and safety of Gardasil and Twinrix when co-administered.
- Trial name
- NCT01456715
- Testing
- Gardasil vaccine, Immunogenicity, Booster dose., Cervarix Vaccine, Immunogenicity, Booster Dose.
- Where
- Canada
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Laval University
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women .
- Trial name
- NCT00250276
- Testing
- Cervarix™
- Where
- 8 sites in Denmark, Lithuania and 1 more
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection Leading to Cervical Cancer
A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.
The purpose of this study was to assess the safety and reactogenicity of GSK Biologicals' Cervarix vaccine in healthy female Filipino subjects from the age of 10 years onwards, as per the Bureau of Food and Drugs Directive of…
- Trial name
- NCT00730847
- Testing
- Cervarix
- Where
- 2 sites in Philippines
- Volunteers
- 743 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
ESCUDDO Long Term Follow Up
This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.
- Trial name
- ESCUDDO LTFU (NCT07706673)
- Testing
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- Costa Rica
- Volunteers
- 13,700 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.